<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04845841</url>
  </required_header>
  <id_info>
    <org_study_id>21665</org_study_id>
    <secondary_id>2020-005715-49</secondary_id>
    <nct_id>NCT04845841</nct_id>
  </id_info>
  <brief_title>Comparison of the Extent to Which the Drug Given as Two Different Capsule Sizes Becomes Available to the Body</brief_title>
  <official_title>Single Center, Randomized, Open-label, Cross-over Study to Investigate the Pharmacokinetics of Two Oral Formulations of Elinzanetant After Single Dosing in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers are looking for a new way to treat women who have symptoms by hormonal changes,&#xD;
      like those that happen in women during menopause. These symptoms can include hot flashes,&#xD;
      night sweats, and changes in blood pressure. These symptoms are caused by hormonal changes&#xD;
      occurring during menopausal transition when women may have also changes in their monthly&#xD;
      cycles. The menopausal transition most often begins between ages 45 and 55 and leads to&#xD;
      menopause, a point in time 12 months after a woman's last period.&#xD;
&#xD;
      The study drug, elinzanetant, was designed to treat symptoms caused by hormonal changes.&#xD;
      Before a new treatment can be approved for people to take, researchers perform clinical&#xD;
      trials to better understand how this treatment works and to investigate safety.&#xD;
&#xD;
      The purpose of this study is to assess the blood levels of elinzanetant when given as 2&#xD;
      capsules of dose A (what is intended for further research and future commercialization) and&#xD;
      also to compare the blood levels when given as 3 capsules of dose B (what was used for&#xD;
      research up to now). Furthermore, researchers want to find out if taking of elinzanetant on&#xD;
      two time points leads to differences in blood levels of elinzanetant.&#xD;
&#xD;
      This trial will be performed in healthy women aged 40 to 65 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 9, 2021</start_date>
  <completion_date type="Actual">June 1, 2021</completion_date>
  <primary_completion_date type="Actual">June 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC of elinzanetant</measure>
    <time_frame>Period 1: Day 1-9, Day 11, Day 13, Day 15; Period 2: Day 1-7, Day 8 (follow up visit)</time_frame>
    <description>AUC: Area under the concentration vs. time curve from zero to infinity after single (first) dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of elinzanetant</measure>
    <time_frame>Period 1: Day 1-9, Day 11, Day 13, Day 15; Period 2: Day 1-7, Day 8 (follow up visit)</time_frame>
    <description>Cmax: Maximum observed drug concentration in measured matrix after single dose administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Approximately 2 to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Approximately 2 to 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Vasomotor Symptoms as a Sex-hormone Dependent Disorder in Women and Men</condition>
  <arm_group>
    <arm_group_label>Participants receive study medication on time point 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive two single doses of elinzanetant in two different treatments in a randomized sequence (Treatment A, Treatment B).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants receive study medication on time point 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive two single doses of elinzanetant in two different treatments in a randomized sequence (Treatment A, Treatment B).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elinzanetant (BAY3427080) treatment A</intervention_name>
    <description>Single oral dose</description>
    <arm_group_label>Participants receive study medication on time point 1</arm_group_label>
    <arm_group_label>Participants receive study medication on time point 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elinzanetant (BAY3427080) treatment B</intervention_name>
    <description>Single oral dose</description>
    <arm_group_label>Participants receive study medication on time point 1</arm_group_label>
    <arm_group_label>Participants receive study medication on time point 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be 40 to 65 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  Participants who are overtly healthy as determined by medical evaluation including&#xD;
             medical history, physical examination, blood pressure, pulse rate, 12-lead&#xD;
             electrocardiogram, body temperature, and laboratory tests.&#xD;
&#xD;
          -  Non-smoker, at least from 3 months before the screening visit onwards&#xD;
&#xD;
          -  Body weight of at least 50 kg and BMI within the range 18.0 and 30.0 kg/m*2&#xD;
             (inclusive) at screening.&#xD;
&#xD;
          -  Female&#xD;
&#xD;
               -  Women of childbearing potential will have to use highly effective non-hormonal&#xD;
                  contraception when having sexual intercourse with a male partner from signing the&#xD;
                  informed consent form until 5 days after last dose of the study drug. Acceptable&#xD;
                  methods of contraception for this study are listed in protocol.&#xD;
&#xD;
               -  Women of non-childbearing potential are not required to use contraception.&#xD;
                  Non-childbearing potential is defined as&#xD;
&#xD;
                    -  Postmenopausal state confirmed by follicle stimulating hormone (FSH) level&#xD;
                       &gt;40 U/L, or above reference range from the local laboratory, or&#xD;
&#xD;
                    -  Surgically sterilized by bilateral tubal ligation, or bilateral oophorectomy&#xD;
                       with or without hysterectomy documented by medical report verification&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
&#xD;
          -  Any clinically relevant abnormal findings in medical history and physical examination&#xD;
             which in the opinion of the investigators, may put the participant at risk because of&#xD;
             her participation in the trial or provide difficulties in interpreting the trial data.&#xD;
&#xD;
          -  History or evidence of any clinically relevant cardiovascular, gastrointestinal,&#xD;
             endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary,&#xD;
             neurologic, dermatologic, psychiatric, renal and/or other clinically relevant disease,&#xD;
             as judged by the investigator.&#xD;
&#xD;
          -  Pre-existing diseases for which it can be assumed that the absorption, distribution,&#xD;
             metabolism, elimination and effects of the study intervention will not be normal.&#xD;
&#xD;
          -  Any medical disorder, condition or history of such that would impair the participant's&#xD;
             ability to participate or complete this study in the opinion of the investigator.&#xD;
&#xD;
          -  Known hypersensitivity to the study interventions (active substances, or excipients of&#xD;
             the preparations).&#xD;
&#xD;
          -  Known severe allergies e.g., allergies to more than 3 allergens, allergies affecting&#xD;
             the lower respiratory tract - allergic asthma, allergies requiring therapy with&#xD;
             corticosteroids, urticaria or significant non-allergic drug reactions.&#xD;
&#xD;
          -  Relevant diseases within the last 4 weeks prior to the first study intervention&#xD;
             administration.&#xD;
&#xD;
          -  Febrile illness within 4 weeks before first study intervention administration.&#xD;
&#xD;
          -  Regular use of medicines.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CRS Clinical-Research-Services Mannheim GmbH</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-WÃ¼rttemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 7, 2021</study_first_submitted>
  <study_first_submitted_qc>April 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2021</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA &quot;Principles for responsible clinical trial data sharing&quot;. This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

